Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259826 | 0.89 | CYP2C9 (0.42) | CNR1RHEBMCL1GRIA2GRIA4 | |
| SCHEMBL1260378 | 0.87 | CNR1 (0.49) | CNR1HSD11B1KMT2A | |
| SCHEMBL2570109 | 0.81 | ESR1 (0.51) | CNR1HSD11B1KMT2A | |
| SCHEMBL1258893 | 0.78 | MARS1 (0.52) | CNR1CCR2KMT2A | |
| SCHEMBL12484647 | 0.78 | RHEB (0.44) | CNR1RHEBMCL1CCR2KMT2A | |
| SCHEMBL1258848 | 0.77 | TACR1 (0.51) | — | |
| SCHEMBL5260699 | 0.76 | PTGES (0.37) | CNR1 | |
| SCHEMBL2906434 | 0.75 | HSD11B1 (0.47) | CNR1HSD11B1 | |
| SCHEMBL1260389 | 0.75 | CNR1 (0.53) | CNR1 | |
| SCHEMBL1260967 | 0.75 | KMT2A (0.43) | CNR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-14 | — | — | US | disclosed |
| US-7381727-B2 | Pyrrole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-03 | — | — | US | disclosed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | PYCR1, FARS2, WEE1 | CNR1 543/4885RHEB 292/4885MCL1 2326/4885 |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PYCR1, PRMT9, PRLHR | CNR1 125/4885RHEB 52/4885MCL1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.